从PCOS到PMOS:更名拓宽生殖照护视野
本文基于Stein-Leventhal早年观察及现代证据,指出多囊卵巢综合征(PCOS)实际不伴卵巢囊肿风险,且患者生育结局可接近未患病女性。2026年5月全球共识将之更名为多内分泌代谢性卵巢综合征(PMOS),作者认为更名是临床 mandate,需拓宽生育与妊娠照护并整合碎片化服务。
要点
- PCOS更名PMOS,强调内分泌代谢负担而非卵巢囊肿。
- 患者累积分娩率可接近未患病女性,但子宫内膜和妊娠并发症是盲点。
- 2028年国际指南更新是语言、编码、试验和临床对齐的具体期限。
核心结论
- 更名PMOS并非表面重贴标签,而是拓宽生育与妊娠照护、整合碎片化服务的临床要求。
研究设计与样本
- 本文为意见类文章,基于Stein和Leventhal(1935)的早期观察及汇总数据展开论述。
主要发现
- 汇总数据显示该综合征涉及多种内分泌和代谢紊乱,但无真正的卵巢囊肿(良性或病理性)风险。
- 现代生育照护下,患者累积分娩率可与未患病女性相当,且可有自然排卵和妊娠,卵巢储备高、绝经较晚。
- 子宫内膜和妊娠并发症一直是生育照护的盲点。
关键数值与推荐
- 2026年5月多步全球共识过程形成《柳叶刀》声明,将疾病更名为多内分泌代谢性卵巢综合征(PMOS)。
- 当前国际指南已开始过渡性采用新名称,下一版主要国际循证指南更新定于2028年。
临床怎么用
- 临床应超越排卵障碍框架,关注内分泌、代谢、心理和肿瘤负担。
- 需整合初级保健、生育、产科和内分泌服务,减少碎片化照护。
- 以2028年指南更新为期限,对齐语言、登记编码、试验方案、教育和临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycystic ovary syndrome (PCOS) has long been focused on the ovary and infertility aspects, rooted in the early observations by Stein and Leventhal (1935). The aggregated data, however, show that the syndrome has a wide comorbidity risk beyond fertility aspects involving several endocrine and metabolic derangements, yet without a true risk of ovarian cysts, benign or pathological, as expected with the old name. Moreover, with modern fertility care, women with the condition can reach cumulative childbirth rates comparable to those of unaffected women. The women may have spontaneous ovulations and pregnancies across the reproductive life course and, having high ovarian reserve, enter the menopause later. The endometrium and pregnancy complications have, however, been the blind spots in fertility care. Taking all this into account, in May 2026, a multi-step global consensus process culminating in a Lancet statement renamed the condition polyendocrine metabolic ovarian syndrome (PMOS), with transitional adoption already underway in current international guidance and consolidation into the next major international evidence-based guideline update scheduled for 2028. This opinion argues that the rename is not a cosmetic relabelling but a clinical mandate to widen fertility and pregnancy care, address fragmented care across primary, fertility, obstetric, and endocrine services, and acknowledge the endocrine, metabolic, psychological, and oncological burden. For Human Reproduction's readership, the 2028 guideline update is the concrete deadline around which language, registry coding, trial protocols, education, and clinical practice can align.
引用
- Piltonen TT, Teede HJ, Bahri Khomami M, et al. Releasing the syndrome from captivity: why renaming PCOS to PMOS widens reproductive care beyond the anovulatory frame. Hum Reprod. 2026. PMID: 42905432. doi:10.1093/humrep/deag150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。